Targeted Effector Fusion Proteins for Reduced Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current targeted drug delivery methods lack efficiency in reducing toxicity and achieving effective dosages for therapeutic treatment of diseases, particularly in inflammation, autoimmune, and periodontal diseases.
Innovation Solution
Development of targeted effector fusion proteins that combine an effector protein, such as indoleamine 2,3 dioxygenase, with a targeting moiety like galectin-3, linked via flexible or alpha coil polypeptides, allowing specific binding to carbohydrates and forming multimeric complexes for enhanced delivery and action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If targeted effector fusion proteins are used to deliver therapeutic agents, then therapeutic effectiveness is improved, but toxicity is reduced
Solution Approach 1:
The effector protein is fused to a targeting moiety that confers specificity to particular cells or tissues expressing certain carbohydrates. This localizes the therapeutic effect to specific target sites while leaving non-target tissues unaffected, thereby improving therapeutic effectiveness while reducing systemic toxicity
Solution Approach 2:
The targeting moiety acts as an intermediary that directs the effector protein to specific target cells through carbohydrate binding. This mediator ensures that the therapeutic agent reaches only the intended destination, enhancing effectiveness at the target site while minimizing exposure and toxicity to healthy tissues
2Adaptability or versatility
If effector proteins are delivered systemically, then broader coverage is achieved, but toxicity increases
Solution Approach 1:
The fusion protein maintains systemic distribution capability while the targeting moiety provides local specificity at the cellular level. This allows broad coverage through systemic administration while the targeting function restricts actual therapeutic action to specific cell types, reducing overall toxicity
3Adaptability or versatility
If fusion proteins are constructed with linkers, then flexibility and multimerization are improved, but structural complexity increases
Solution Approach 1:
The alpha coil polypeptide linker is designed to self-assemble through coiled-coil interactions, automatically forming multimeric structures without requiring external assembly mechanisms. This self-organizing property provides flexibility and multimerization capability while keeping the structural design relatively simple and predictable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted effector fusion proteins effectively reduce inflammation and autoimmune responses by specifically targeting and binding to cells, reducing cytokine secretion and modulating metabolism, thereby improving therapeutic outcomes with reduced toxicity.
Implementation Method 1
The targeting moiety can be capable of specifically binding to a carbohydrate
Implementation Method 2
The alpha coil polypeptide can be capable of multimerizing with one or more other alpha coils that are integrated in one or more other targeted effector proteins
Implementation Method 3
The effector protein can be an enzyme. The enzyme can be indoleamine 2,3 dioxygenase
Data Source
AI summary
Provided herein are targeted effector fusion proteins, complexes thereof, and uses thereof. The targeted effector fusion proteins can include an effector protein that can be linked to a targeting moiety. Monomer targeted effector fusion proteins can form homogeneous or heterogeneous complexes. The targeted effector fusion proteins and complexes thereof can be formulated as pharmaceutical formulations. The targeted effector fusion proteins, complexes thereof, and formulations thereof can be administered to a subject in need thereof.